JP7671275B2 - 動物用の抗ｉｌ３１抗体 - Google Patents

動物用の抗ｉｌ３１抗体 Download PDF

Info

Publication number
JP7671275B2
JP7671275B2 JP2022511238A JP2022511238A JP7671275B2 JP 7671275 B2 JP7671275 B2 JP 7671275B2 JP 2022511238 A JP2022511238 A JP 2022511238A JP 2022511238 A JP2022511238 A JP 2022511238A JP 7671275 B2 JP7671275 B2 JP 7671275B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022511238A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021041972A5 (https=
JP2022545259A (ja
JP2022545259A5 (https=
Inventor
シー ジアン リー，
ラム グェン，
ハンチュン チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco US Inc filed Critical Elanco US Inc
Publication of JP2022545259A publication Critical patent/JP2022545259A/ja
Publication of JPWO2021041972A5 publication Critical patent/JPWO2021041972A5/ja
Publication of JP2022545259A5 publication Critical patent/JP2022545259A5/ja
Application granted granted Critical
Publication of JP7671275B2 publication Critical patent/JP7671275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022511238A 2019-08-29 2020-08-28 動物用の抗ｉｌ３１抗体 Active JP7671275B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893799P 2019-08-29 2019-08-29
US62/893,799 2019-08-29
US201962894526P 2019-08-30 2019-08-30
US62/894,526 2019-08-30
PCT/US2020/048618 WO2021041972A1 (en) 2019-08-29 2020-08-28 Anti-il31 antibodies for veterinary use

Publications (4)

Publication Number Publication Date
JP2022545259A JP2022545259A (ja) 2022-10-26
JPWO2021041972A5 JPWO2021041972A5 (https=) 2023-09-04
JP2022545259A5 JP2022545259A5 (https=) 2023-09-04
JP7671275B2 true JP7671275B2 (ja) 2025-05-01

Family

ID=74686094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511238A Active JP7671275B2 (ja) 2019-08-29 2020-08-28 動物用の抗ｉｌ３１抗体

Country Status (10)

Country Link
US (1) US20220324960A1 (https=)
EP (1) EP4021499A4 (https=)
JP (1) JP7671275B2 (https=)
KR (1) KR20220071191A (https=)
CN (1) CN114555121A (https=)
AU (1) AU2020336210A1 (https=)
BR (1) BR112022002771A2 (https=)
CA (1) CA3147809A1 (https=)
MX (1) MX2022002360A (https=)
WO (1) WO2021041972A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN114989299B (zh) * 2022-06-21 2023-05-26 北京索莱宝科技有限公司 一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法
CN117186220A (zh) * 2023-07-20 2023-12-08 北京伟杰信生物科技有限公司 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
CN120865402A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
CN121108334A (zh) * 2024-06-11 2025-12-12 优迈生物科技(连云港)有限公司 抗犬il-31的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
CN102321174B (zh) * 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
GB2504887B (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
HK1201281A1 (en) * 2011-10-13 2015-08-28 Nexvet Australia Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US9499621B2 (en) * 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
KR20170134748A (ko) * 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN109789201B (zh) * 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
WO2020056393A1 (en) * 2018-09-14 2020-03-19 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin. Transl. Allergy，2018年，Vol.8, No.41，pp.1-12
Veterinary Dermatology，2019年，Vol.30，pp.277-306

Also Published As

Publication number Publication date
EP4021499A4 (en) 2024-08-07
EP4021499A1 (en) 2022-07-06
BR112022002771A2 (pt) 2022-08-09
US20220324960A1 (en) 2022-10-13
AU2020336210A1 (en) 2022-03-03
JP2022545259A (ja) 2022-10-26
WO2021041972A1 (en) 2021-03-04
CN114555121A (zh) 2022-05-27
CA3147809A1 (en) 2021-03-04
KR20220071191A (ko) 2022-05-31
MX2022002360A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
US12435132B2 (en) Anti-IL31 antibodies for veterinary use
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
US20220049002A1 (en) Anti-IL4 Receptor Antibodies for Veterinary Use
US12583917B2 (en) IL17A antibodies and antagonists for veterinary use
WO2018156367A1 (en) Anti-il31 antibodies for veterinary use
US20230312702A1 (en) Long-acting anti-il31 antibodies for veterinary use
RU2835543C1 (ru) Анти-il31 антитела для применения в ветеринарии
RU2795485C2 (ru) Анти-il31 антитела для применения в ветеринарии
EA051516B1 (ru) Анти-il31 антитела для применения в ветеринарии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250321

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150